Skip to main content

Table 1 Demographic characteristics of patients with adverse drug events (ADEs) leading to Emergency Departments (ED) visits

From: Characterization and preventability of adverse drug events as cause of emergency department visits: a prospective 1-year observational study

  ADE-related ED visits Serious ADE-related
ED visits
Not serious ADE-related
ED visits
No. of Cases (%) 95% CI No. of Cases (%) 95% CI No. of Cases (%) 95% CI
Gender
aMales 212 (36.9) 32.9–40.8 59 (34.7) 27.5–41.9 149 (37.2) 32.4–41.9
Females 363 (63.1) 59.2–67.1 111 (65.3) 58.1–72.5 252 (62.8) 58.1–67.6
Patient age group, years
b18–34 118 (20.5) 17.2–23.8 27 (15.6) 10.2–21.0 86 (22.2) 18.1–26.3
c35-49 143 (24.1) 20.6–27.5 23 (13.3) 8.2–18.4 118 (28.3) 24.0–32.6
50–64 150 (25.3) 21.8–28.7 39 (22.5) 16.3–28.8 111 (26.6) 22.4–30.9
65–79 116 (19.5) 16.3–22.7 52 (30.1) 23.2–36.9 64 (15.3) 11.9–18.8
≥80 48 (8.1) 5.9–10.3 29 (16.8) 11.2–22.3 19 (4.6) 2.6–6.6
No. of medications by category
d1 380 (66.1) 62.2–70.0 57 (33.5) 26.4–40.6 319 (79.6) 75.6–83.5
≥2 195 (33.9) 30.0–37.8 113 (66.5) 59.4–73.6 85 (20.4) 16.5–24.4
Preventability assessment
Certainly preventable 71 (12.3) 9.7–15.0 42 (24.7) 18.2–31.2 29 (7.2) 4.7–9.8
Probably preventablee 336 (58.4) 54.4–62.5 101 (59.4) 52.0–66.8 232 (57.9) 53.0–62.7
Not-preventablef 168 (29.2) 25.5–32.9 27 (15.9) 10.4–21.4 140 (34.9) 30.2–39.6
  1. 95% CI 95% confidence interval
  2. a4 patients with unspecified ADE seriousness
  3. b2 patients with unspecified ADE seriousness
  4. c2 patients with unspecified ADE seriousness
  5. d4 patients with unspecified ADE seriousness
  6. e3 patients with unspecified ADE seriousness
  7. f1 patient with unspecified ADE seriousness